Market Research Logo

Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2015


Attention: There is an updated edition available for this report.

Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2015’, provides an overview of the Exocrine Pancreatic Insufficiency’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Exocrine Pancreatic Insufficiency and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Exocrine Pancreatic Insufficiency and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Exocrine Pancreatic Insufficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Exocrine Pancreatic Insufficiency pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Exocrine Pancreatic Insufficiency
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Exocrine Pancreatic Insufficiency Overview
Therapeutics Development
Pipeline Products for Exocrine Pancreatic Insufficiency - Overview
Pipeline Products for Exocrine Pancreatic Insufficiency - Comparative Analysis
Exocrine Pancreatic Insufficiency - Therapeutics under Development by Companies
Exocrine Pancreatic Insufficiency - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Exocrine Pancreatic Insufficiency - Products under Development by Companies
Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development
Actavis plc
Anthera Pharmaceuticals‚ Inc.
Cilian AG
Laboratoires Mayoly Spindler S.A.S.
Nordmark Arzneimittel GmbH & Co. KG
Exocrine Pancreatic Insufficiency - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
burlulipase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cilase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enzyme to Replace Lipase for Exocrine Pancreatic Insufficiency - Drug Profile
Product Description
Mechanism of Action
R&D Progress
liprotamase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MS-1819 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pancrelipase DR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Exocrine Pancreatic Insufficiency - Recent Pipeline Updates
Exocrine Pancreatic Insufficiency - Dormant Projects
Exocrine Pancreatic Insufficiency - Discontinued Products
Exocrine Pancreatic Insufficiency - Product Development Milestones
Featured News & Press Releases
Nov 20, 2014: Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
Dec 10, 2012: Aptalis Pharma Announces US Commercial Availability Of Ultresa Delayed-release Capsules
Aug 01, 2012: Cilian Receives €1m Grant For Development Of Cilase
Mar 01, 2012: Aptalis Pharma Receives FDA Approval For ULTRESA Pancrelipase Delayed Release Capsules
Jul 14, 2011: Aptalis Pharma Receives FDA Approval Of 25,000 Lipase-Unit Strength Of ZENPEP
Jun 17, 2011: Aptalis Pharma Receives FDA Approval For New Low Strength Of ZENPEP
Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency
Feb 11, 2011: Axcan Completes Acquisition of Eurand and Commences Subsequent Offering Period
Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase
Jan 12, 2011: Eurand Announces Agreement With Nycomed for ZENPEP in Russia-CIS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2015
Number of Products under Development for Exocrine Pancreatic Insufficiency - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Exocrine Pancreatic Insufficiency - Pipeline by Actavis plc, H1 2015
Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2015
Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H1 2015
Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler S.A.S., H1 2015
Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co. KG, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Exocrine Pancreatic Insufficiency Therapeutics - Recent Pipeline Updates, H1 2015
Exocrine Pancreatic Insufficiency - Dormant Projects, H1 2015
Exocrine Pancreatic Insufficiency - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2015
Number of Products under Development for Exocrine Pancreatic Insufficiency - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report